Búsqueda avanzada

Karl-Ludwig Kley es un empresario alemán que ha estado al frente de 7 empresas diferentes. Ocupa el cargo de Presidente del Consejo de Supervisión de E.ON SE, Presidente del Consejo de Supervisión de Deutsche Lufthansa AG y Codirector General de Glasbau Hahn GmbH. El Dr. Kley también forma parte del consejo de Bayerische Motoren Werke AG, de la Fritz Thyssen Stiftung y de la Deutsche Akademie der Technikwissenschaften eV y es presidente del consejo de administración de Baden Badener Unternehmergesprche, vicepresidente de la Bundesverband der Deutschen Industrie eV, miembro del consejo ejecutivo de E. Merck KG y vicepresidente de la Verband der Chemischen Industrie eV. En su anterior carrera, el Dr. Kley fue Presidente del Consejo de Administración de Merck KGaA, Director de Finanzas Corporativas y Relaciones con los Inversores de Bayer AG y Director Financiero de Bayer Holding Ltd. (una filial de Bayer AG). (filial de Bayer AG), Presidente del Consejo de Supervisión de Lufthansa AirPlus Servicekarten GmbH, Presidente del Consejo de Supervisión de 1. FC Kln GmbH & Co. KGaA, Director del Consejo de Administración de KG Allgemeine Leasing GmbH & Co. y Jefe de la División Farmacéutica de Bayer SpA. El Dr. Kley se doctoró, se licenció y se graduó en la Ludwig-Maximilians-Universitt Mnchen.

Karl-Ludwig Kamprath formerly worked at Deutsche Sparkassen Leasing AG & Co. KG, as Chairman-Supervisory Board, Kreissparkasse München Starnberg Ebersberg, as Chairman, Deutsche Leasing AG, as Chairman-Supervisory Board, LfA Förderbank Bayern, as Director-Management Board, BayernLB Holding AG, as Director, GTU Geothermie Unterschleißheim AG, as Director-Supervisory Board from 2010 to 2012, and Baader Bank AG, as Member-Supervisory Board from 2010 to 2018.

Nikolai Kley is the founder of two companies, FORMA Therapeutics, Inc. (founded in 2008) and Orionis Biosciences, Inc. (founded in 2015).
At FORMA Therapeutics, he held the title of VP-Biology & Head-Drug Discovery Research from 2008 to 2011.
At Orionis Biosciences, he held the titles of President, Chief Executive Officer & Director from 2015 to present, and currently holds the titles of Managing Director & Director at Orionis Biosciences BV since 2015 and Professor at Princeton University.
He previously worked at Bristol Myers Squibb Co. as a Principal, GPC Biotech AG as a Vice President, The General Hospital Corp.
as a Fellow, Genome Therapeutics Corp.
as a Vice President, and Harvard Medical School as a Fellow.
He received his undergraduate degree from the University of Leeds and doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.

Mr. Jason B.
Kley is Senior Integrated Wealth Advisor at Carlson Capital Management, Inc. He is a member of the Minnesota Financial Planning Association.
Before joining the CCM, Mr. Kley worked for a Minneapolis wealth management firm where he served as a financial advisor, investment committee member, and 401k plan specialist.
Prior to that, he worked for Thrivent Financial and Union Pacific, serving in business analyst and strategic operational roles.
Mr. Kley has also served on the Minneapolis Regional Chamber of Commerce DRIVE Emerging Leaders Board, Best Prep’s Minnesota Business Venture Advisory Committee, and the City of St. Louis Park Police Advisory Commission.
He holds a Bachelor of Arts degree in Math and Computer Science from the University of St. Thomas where he graduated magna cum laude in 1998.
He also earned an MBA with an emphasis in Finance and Strategy from Washington University in St. Louis, Missouri.

Karl-Ludwig Diehl is currently a Managing Director-Germany at Woodbridge International LLC.
He obtained an undergraduate degree from Friedrich-Alexander University of Erlangen-Nuremberg.